Siemens Showcases IT Solutions for Driving Greater Value in Radiology
June 2nd 2011(Press Release) Siemens Healthcare will showcase its portfolio of imaging information technology (IT) and workflow management solutions at the Society for Imaging Informatics in Medicine (SIIM) 2011 Annual Meeting from June 2-5, 2011, (booth 825) in the Gaylord National Resort and Convention Center, Washington, D.C.
TeraRecon, Inc. Highlights Integration and Interconnectivity of iNtuition
June 2nd 2011(Press Release) TeraRecon, Inc. (www.terarecon.com), a leader in advanced visualization and decision support, today highlighted Integration and Interconnectivity of the iNtuitionTM enterprise advanced visualization solution to imaging and informatics professionals assembled for the Annual Meeting of the Society of Imaging Informatics in Medicine (SIIM),
BRIT Systems, Inc., Announces New Version of its PACS Workstation
June 2nd 2011(Press Release) The major enhancements of this release include the introduction of the 64-bit Ubuntu operating system, performance and speed enrichments, seamless interoperability with Roentgen Works advanced workflow tools such as ER Discordance, Urgent Findings and On Holds, and an improvement in the comparison tools for hanging protocols.
Contrast Media Reactions Are Allergic, but Minor
March 9th 2011Final results of the prospective French CIRTACI trial are in: contrast media for diagnostic imaging are very safe in general, as long as radiologists are vigilant for patients with allergies, asthma, or previous reactions to contrast agents. The vast majority are more itchy than serious.
Reducing CT Coronary Angiography Radiation, Maintaining Imaging Quality
March 7th 2011Through carefully calculated adjustments to coronary imaging using dose-reduction techniques, cardiologists have managed to reduce the radiation delivered to patients undergoing coronary angiograms considerably. Plus, it’s possible to maintain good image quality throughout, researchers found
Breast Cancer Screening in 2025: Mammography, MRI, or More?
March 7th 2011Will we still be using mammography for breast cancer screening one fourth of the way through this century? That was the question posed in one session at ECR 2011, and speaker Christine Kuhl said she greatly fears that we actually may.
Which Test is Best for Cardiac Triage?
March 7th 2011Just this month, cardiovascular surgeons and diagnostic radiologists collaborated to publish an article showing that CT is much better than ultrasound at measuring the diameter of the aortic annulus - an important matter when deciding which size of valve to implant transcutaneously. This could both dishearten and encourage radiologist Rodrigo Salgado of Antwerp University Hospital, who says CT is best for measuring the annulus, and that isn't circular, doesn’t have a radius, and in fact actually doesn't exist.
Contrast MRI Best at Finding Liver Trouble - But Timing Matters
March 6th 2011For spotting the tiniest metastases inside the liver, MRI with the liver-specific gadolinium-based contrast agent Primovist (gadoxetic acid) was far and away the top choice of surgeons in an eight-country multicenter study. The surgeons were given a chance to use various imaging methods for colorectal center patients and judge their value. The same contrast agent is also proving adept at visualizing obstructions in biliary vasculature, compared to non-contrast-enhanced MRI.
MRI Improvements Show Promise for Myocardial Infarction
March 4th 2011Refinements in MRI technique continue to show promise in clarifying the nature and extent of damage of myocardial infarction. Take for example teams from Munich, Germany presenting this week at ECR 2011, who have been finding ways around the problem of adapting inversion time to the individual patient when using delayed enhancement to detect tissue damage.
Requiem for a Panic Attack: More Large Studies Vindicate Gadolinium Contrast
March 4th 2011Five years after the first reports linking gadolinium-based MRI contrast agents to nephrogenic system fibrosis (NSF), separate presentations of post-marketing data from manufacturers and an independent prospective study supported by agencies in France have validated the low-risk status of the contrast agent Dotarem (Gd-DOTA).